BR112022020320A2 - Método para manter uma concentração terapeuticamente eficaz de endoxifeno para tratamento de um paciente com distúrbio bipolar i - Google Patents
Método para manter uma concentração terapeuticamente eficaz de endoxifeno para tratamento de um paciente com distúrbio bipolar iInfo
- Publication number
- BR112022020320A2 BR112022020320A2 BR112022020320A BR112022020320A BR112022020320A2 BR 112022020320 A2 BR112022020320 A2 BR 112022020320A2 BR 112022020320 A BR112022020320 A BR 112022020320A BR 112022020320 A BR112022020320 A BR 112022020320A BR 112022020320 A2 BR112022020320 A2 BR 112022020320A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- patient
- endoxifen
- bipolar
- disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Abstract
MÉTODO PARA MANTER UMA CONCENTRAÇÃO TERAPEUTICAMENTE EFICAZ DE ENDOXIFENO PARA TRATAMENTO DE UM PACIENTE COM DISTÚRBIO BIPOLAR I. Trata-se de um método para manter uma concentração terapeuticamente eficaz de endoxifeno para o tratamento de paciente com distúrbio bipolar I. O método inclui administrar ao paciente uma dose de 2 mg a 16 mg de citrato de endoxifeno em um comprimido com revestimento entérico uma vez ao dia por pelo menos 21 dias. Adicionalmente, o dito método fornece um perfil de plasma in vivo desejável. O monitoramento de dose terapêutica não é necessário em um paciente submetido ao dito tratamento. Adicionalmente, o método fornece uma melhora significativa em mania avaliada pelas pontuações YMRS e MADRS no paciente submetido ao dito tratamento. Adicionalmente, o método fornece um tempo de resposta precoce do tratamento em pelo menos 2 dias e tempo de remissão que é no máximo 4 dias no paciente submetido ao dito tratamento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063008141P | 2020-04-10 | 2020-04-10 | |
| PCT/IB2021/052970 WO2021205402A1 (en) | 2020-04-10 | 2021-04-09 | Endoxifen for the treatment of bipolar i disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022020320A2 true BR112022020320A2 (pt) | 2022-12-13 |
Family
ID=78005740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022020320A BR112022020320A2 (pt) | 2020-04-10 | 2021-04-09 | Método para manter uma concentração terapeuticamente eficaz de endoxifeno para tratamento de um paciente com distúrbio bipolar i |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11291640B2 (pt) |
| EP (1) | EP4132497A4 (pt) |
| CN (1) | CN115484941A (pt) |
| AU (1) | AU2021252229A1 (pt) |
| BR (1) | BR112022020320A2 (pt) |
| CA (1) | CA3177260A1 (pt) |
| MX (1) | MX2022012519A (pt) |
| WO (1) | WO2021205402A1 (pt) |
| ZA (1) | ZA202211308B (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12245997B2 (en) * | 2020-04-10 | 2025-03-11 | Jina Pharmaceuticals, Inc. | Endoxifen for the treatment of bipolar I disorder |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2101731T (pt) | 2006-11-21 | 2018-04-18 | Jina Pharmaceuticals Inc | Endoxifeno para utilização no tratamento de cancro |
| US20090291134A1 (en) * | 2006-11-21 | 2009-11-26 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases |
| US20120164075A1 (en) | 2006-11-21 | 2012-06-28 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of mammalian diseases |
| WO2009120999A2 (en) * | 2008-03-28 | 2009-10-01 | Olema Pharmaceuticals, Inc. | Use of an endoxifen prodrug for treatment of breast cancer |
| KR101308258B1 (ko) | 2010-10-15 | 2013-09-13 | 씨제이제일제당 (주) | 엔독시펜의 신규한 제조 방법 |
| WO2014141292A2 (en) | 2013-03-04 | 2014-09-18 | Intas Pharmaceuticals Limited | Endoxifen citrate polymorph and process for preparing the same |
-
2021
- 2021-04-09 BR BR112022020320A patent/BR112022020320A2/pt unknown
- 2021-04-09 WO PCT/IB2021/052970 patent/WO2021205402A1/en not_active Ceased
- 2021-04-09 MX MX2022012519A patent/MX2022012519A/es unknown
- 2021-04-09 AU AU2021252229A patent/AU2021252229A1/en active Pending
- 2021-04-09 CN CN202180031809.9A patent/CN115484941A/zh active Pending
- 2021-04-09 EP EP21784506.4A patent/EP4132497A4/en active Pending
- 2021-04-09 US US17/226,628 patent/US11291640B2/en active Active
- 2021-04-09 CA CA3177260A patent/CA3177260A1/en active Pending
-
2022
- 2022-10-14 ZA ZA2022/11308A patent/ZA202211308B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4132497A1 (en) | 2023-02-15 |
| AU2021252229A1 (en) | 2022-10-27 |
| WO2021205402A1 (en) | 2021-10-14 |
| MX2022012519A (es) | 2023-01-16 |
| ZA202211308B (en) | 2024-02-28 |
| EP4132497A4 (en) | 2024-04-24 |
| US20210315843A1 (en) | 2021-10-14 |
| CN115484941A (zh) | 2022-12-16 |
| US11291640B2 (en) | 2022-04-05 |
| CA3177260A1 (en) | 2021-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022020732A2 (pt) | Método de dosagem e tratamento de pacientes com um psicodélico, método para determinar uma dose de um psicodélico para um indivíduo, método para definir doses terapêuticas de um psicodélico em ensaios clínicos, método para tratar afecções psiquiátricas em um indivíduo, métodos de terapia, e método para monitorar indivíduos para depressão após tratamento com lsd | |
| EP4487908A3 (en) | Methods of treating crohn's disease and ulcerative colitis | |
| Moore et al. | Head and thorax elevation during active compression decompression cardiopulmonary resuscitation with an impedance threshold device improves cerebral perfusion in a swine model of prolonged cardiac arrest | |
| AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| BR112014018485A8 (pt) | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf | |
| MX2023012875A (es) | Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef. | |
| AR114392A1 (es) | Tratamiento de pacientes con enfermedad de fabry clásica | |
| BR112022020320A2 (pt) | Método para manter uma concentração terapeuticamente eficaz de endoxifeno para tratamento de um paciente com distúrbio bipolar i | |
| Pozzi et al. | Airway closure in patients with cardiogenic pulmonary edema as a cause of driving pressure overestimation: the “uncorking effect” | |
| Brander et al. | Neural control of ventilation prevents both over-distension and de-recruitment of experimentally injured lungs | |
| Long et al. | Effects of adenosine triphosphate (atp) on early recovery after total knee arthroplasty (tka): a randomized, double-blind, controlled study | |
| Mathan et al. | Olanzapine-induced tender pitting pre-tibial edema | |
| Dream et al. | Refractory ventricular fibrillation in patient taking Lamictal | |
| Knapp et al. | Effects of adenosine monophosphate on induction of therapeutic hypothermia and neuronal damage after cardiopulmonary resuscitation in rats | |
| Ali et al. | The Effect of Ketamine-Propofol Administration versus Propofol on Hemodynamic Stability during Induction and Intubation and Maintenance of Anesthesia | |
| BR112022020322A2 (pt) | Método para gerenciar ou diminuir um risco de efeitos adversos em um paciente submetido ao tratamento de distúrbio bipolar i | |
| Nakamura et al. | Improvement of catatonia-induced rapid respiratory failure with electroconvulsive therapy: A case report | |
| Munerato et al. | Return of spontaneous circulation after cardiopulmonary arrest in an adult horse recovering from anaesthesia | |
| Chen et al. | Clinical study on electroacupuncture for perimenopausal insomnia | |
| WO2025264860A3 (en) | Methods of treating post-covid airway disease | |
| Or et al. | Ards Treatment | |
| CA3177266A1 (en) | Endoxifen for the treatment of bipolar i disorder | |
| EP4241838A3 (en) | Use of ribose for treatment of subjects having congestive heart failure | |
| BR112021026463A2 (pt) | Métodos para identificar um indivíduo a ser tratado por tempo de sono atrasado, para identificar um indivíduo em que o tempo de sono ou fase de sono pode ser atrasada, para identificar um indivíduo a ser tratado para um período circadiano alongado (tau), para identificar um indivíduo como alguém passível de alteração de um período circadiano (tau), e, para identificar um paciente a ser tratado para uma fase de sono atrasado devido ao tratamento com um inibidor de canal de nucleotídeo cíclico ativado por hiperpolarização (hcn) | |
| Vettori et al. | FRI0446 Severe Heart Disease in Systemic Sclerosis: Prevalence, Risk Factors and Current Treatment. A Eustar-Desscipher Study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |